Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...
Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s ...
Fintel reports that on March 3, 2025, B of A Securities downgraded their outlook for Zai Lab Limited - Depositary Receipt () ...
Fintel on MSN4d
Scotiabank Initiates Coverage of Zai Lab Limited - Depositary Receipt () (ZLAB) with Sector Outperform RecommendationFintel reports that on March 7, 2025, Scotiabank initiated coverage of Zai Lab Limited - Depositary Receipt () (NasdaqGM:ZLAB ...
Scotiabank initiated coverage of Zai Lab (ZLAB) with an Outperform rating and $55 price target The firm says that although geopolitical risk ...
Zacks Investment Research on MSN8d
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a BetShares of Zai Lab Limited Unsponsored ADR (ZLAB) have gained 15.9% over the past four weeks to close the last trading session at $31.73, but there could still be a solid upside left in the stock if ...
BofA downgraded Zai Lab (ZLAB) to Neutral from Buy with a price target of $36.10, up from $29. The firm cites the growth slowdown of the ...
Investor's Business Daily on MSN13d
China Biotech's Sales Jump 66% But Bottom Line Misses ViewsZai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base.
Scotiabank initiated coverage on shares of Zai Lab (NASDAQ:ZLAB – Free Report) in a research note issued to investors on Friday morning, Ratings reports. The firm issued a sector outperform rating and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback